【摘要】 目的 :研究青蒿琥酯的抗肝癌作用。方法 :运用小鼠肝癌H2 2 癌模型、MTT法和集落形成法 ,观察青蒿琥酯对荷瘤鼠和人肝癌SMMC 772 1细胞株的作用。结果 :口服青蒿琥酯 30 0mg·kg-1·d-1,肿瘤受到明显抑制 ,抑瘤率在 3次实验中分别为 49.1% ,48.7% ,46 .6 % ;小鼠生存时间明显延长。青蒿琥酯与 5 氟尿嘧啶有协同抗肿瘤作用。青蒿琥酯体外对人肝癌细胞有明显细胞毒作用 ,其IC50 为 2 .0 7μg·ml-1,同时抑制人肝癌SMMC 772 1克隆原细胞形成集落 ,其IC50 为 2 .48μg·ml-1。结论 :口服青蒿琥酯有抗肝肿瘤作用更多还原

【Abstract】 Objective:To observe the inhibiting effect of Artesunate on liver cancer in vitro and in vivo. Method: The mice bearing H 22 solid and ascitic liver tumor were applied in vivo experiments. Microculture tetrazolium assay and colony forming unit assay were applied to test the cytotoxicity to human hepatocarcinoma SMMC 7721cell line in vitro. Result:The growth of solid tumor were obviously inhibited by Artesunate at the dose of 300 mg·kg -1 ·d -1 ig for 7days. The tumor inhibiting rates of Artesunate were 49.1%, 48.7%, 46.6% in 3 experiments respectively. After administration of Artesunate, the survival rate of the mice bearing H 22 ascitic liver tumor were increased to 45%. Compaired with the control groups, the difference was statistically significant ( P <0.01). In additional, Artesunate can synergize the antitumor activity of 5 fluorouracil. Artesunate showed evident cytotoxicity to human hepatocarcinoma SMMC 7721 cells, the IC 50 of Artesunate being 2.07 μg·ml -1 in MTT experiment and 2.48 μg·ml -1 in colony forming unit experiment. Conclusion:Artesunate has marked antitumor activity in vitro and in vivo.更多还原